Your Health, We Care
Another NameTruqap、卡帕塞替尼、Capivasertib
IndicationsIt is indicated for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer who have disease progression after hormone therapy
Reg No.08 L 1167/24
Inspection NO.1543-24
Capivasertib (trade name: TRUQAP) is a prescription oral medication approved for marketing by the U.S. Food and Drug Administration (FDA) in 2023. Its targeted indications include mutations in PIK3CA, AKT1 and PTEN, and it must be used strictly in accordance with the doctor’s instructions.
PIK3CA
AKT1
PTEN
Capivasertib can inhibit the oncogenic signaling pathways driven by genetic variations in PIK3CA, AKT1 or PTEN.
Route and Frequency of Administration for Capivasertib: 400 mg, oral administration, twice daily.
The dosage of Capivasertib needs to be adjusted according to the patient’s actual condition. For specific circumstances, please consult a doctor and follow the doctor’s advice closely.
Recommended Reading: Dosage and Administration of Capivasertib
Severe Adverse Reactions: Hyperglycemia (diabetes mellitus), diarrhea, skin reactions.
Most Common Adverse Reactions: Nausea, fatigue, vomiting, oral ulcers and changes in certain blood test results.
Reference Article: Adverse Reactions of Capivasertib
Pregnancy: If you are pregnant or planning to become pregnant, Capivasertib may harm your unborn baby.
Lactation: If you are breastfeeding or planning to breastfeed, do not breastfeed during the treatment with Capivasertib. Please consult your doctor for the best way to feed your baby during the treatment with Capivasertib.
During the treatment with Capivasertib, you should not drink grapefruit juice or eat grapefruits.
from FDA，2024.09
